Cardiovascular effects of YM430, a 1,4-dihydropyridine derivative with β-adrenoceptor blocking activity, in dogs and rats

Biological and Pharmaceutical Bulletin

Volumn 20, Issue 3, 1997, Pages 230-236

  Shibasaki, Kumiko ^a   Uchida, Wataru ^a   Takizawa, Kenji ^a   Masuda, Noriyuki ^a   Okazaki, Toshio ^a   Inagaki, Osamu ^a   Asano, Masaharu ^a   Takenaka, Toichi ^a  

^a ASTELLAS PHARMA INC   (Japan)

Author keywords

antiangina; calcium antagonist; cardiovascular effect; hypotension; YM430; blocker

Indexed keywords

1,4 DIHYDROPYRIDINE DERIVATIVE; ANTIANGINA PECTORIS AGENT; ANTIHYPERTENSIVE AGENT; ATENOLOL; BETA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; ISOPRENALINE; NIFEDIPINE; UNCLASSIFIED DRUG; YM 430;

ANGINA PECTORIS; ANIMAL EXPERIMENT; ANTIHYPERTENSIVE ACTIVITY; ARTERY BLOOD FLOW; ARTICLE; ATRIOVENTRICULAR CONDUCTION; BETA ADRENERGIC RECEPTOR BLOCKING; BLOOD PRESSURE; CARDIOVASCULAR EFFECT; CONTROLLED STUDY; DOG; DOSE RESPONSE; FEMALE; HEART LEFT VENTRICLE PRESSURE; HEART RATE; HYPERTENSION; INTRAVENOUS DRUG ADMINISTRATION; MALE; NONHUMAN; ORAL DRUG ADMINISTRATION; RAT; VASCULAR RESISTANCE;

EID: 0030975206     PISSN: 09186158     EISSN: None     Source Type: Journal    
DOI: 10.1248/bpb.20.230     Document Type: Article

References (18)

1. Oparil S., Calhoun D. A., Am. J. Hypertens., 4, 396S-405S (1991).
2. Nayler W. G., Drugs, 35 (supple. 4), 1-8 (1988).
3. Frishman W., Silverman R., Strom J., Elkayam U., Sonnenblick E., Am. Heart. J., 98, 256-262 (1979).
4. Fleckenstein A., "Calcium and the Heart," ed. by Harris P., Opie L., Academic Press, Orlando, 1971, pp. 135-188.
5. Wolfson S., Heinle R. A., Herman M. V., Kemp H. G., Sullivan J. M., Gorlin R., Am. J. Cardiol., 18, 345-353 (1966).
6. Pedersen O. L., Mikkelsen E., Eur. J. Clin. Pharmacol., 14, 375-381 (1978).
7. Olivari M. T., Bartorelli C., Polese A., Fiorentini C., Moruzzi P., Guazzi M. D., Circulation, 59, 1056-1062 (1979).
8. Robertson R. M., Wood A. J. J., Vaughn W. K., Robertson D., Circulation, 65, 281-285 (1982).
9. Leon M. B., Rosing D. R., Bonow R. O., Epstein S. E., Am. J. Cardiol., 55, 69B-80B (1985).
10. Dargie H. J., Drugs, 35, 44-50 (1988).
11. Dahlof B., Eggertsen R., Hansson L., J. Cardiovasc. Pharmacol., 12, S104-108 (1988).
12. Uchida W., Takizawa K., Shibasaki K., Asano M., Eur. J. Pharmacol., 183, 1322-1323 (1990).
13. Shibasaki K., Uchida W., Shirai Y., Inagaki O., Asano M., Takenaka T., Arch. Int. Pharmacodyn. Ther., 328, 213-224 (1994).
14. Takenaka T., Asano M., Shiono K., Shibasaki M., Inagaki O., Br. J. Clin. Pharmacol., 20, 7S-22S (1985).
15. Uchida Y., Jpn. Heart J., 23, 981-988 (1982).
16. Uchida W., Shibasaki K., Asano M., J. Cardiovasc. Pharmacol., 19, 60-68 (1992).
17. Nakao K., Kato H., Takagi K., Jpn. J. Pharmacol., 25, 25-34 (1975).
18. Conway J., Darwin K., Hilditch A., Loveday B., Reeves M., Clin. Sci. Mol. Med., 2, 101S-103S (1975).